Safety and efficacy of mesenchymal stem cells in the treatment of ischemic stroke: a meta-analysis

doi:10.12307/2022.981

Abstract

Abstract: OBJECTIVE: To systematically evaluate the safety and efficacy of mesenchymal stem cells in the treatment of ischemic stroke, and to provide relevant evidence-based medicine evidence.
METHODS: Clinical controlled trials of mesenchymal stem cells in the treatment of stroke were searched from Chinese databases (CNKI, Wanfang, and VIP) and English databases (PubMed, The Cochrane Library, and Embase) for articles published until September 30, 2021. The United States National Institutes of Health Stroke Scale score, Barthel index, Fugl-Myer movement assessment score, functional independence measure score, and Modified Rankin Scale score were used as outcome measures. Literature screening, data extraction and research quality assessment were conducted independently by two researchers. The qualities of randomized controlled trials were assessed using Cochrane bias risk assessment tool. Stata 15.0 was used for meta-analysis, sensitivity analysis and forest plot making.
RESULTS: A total of 1 127 patients with ischemic stroke were included from 20 randomized controlled trials. The overall quality of the literature was high. Meta-analysis results showed that the scores of National Institutes of Health Stroke Scale, Fugl-Myer movement assessment and functional independence measure score in the mesenchymal stem cell group were better than those in the control group after 3 months of treatment [WMD=-2.12(95%CI:-2.66 to -1.58, Z=7.70, P < 0.001), WMD=14.34(95%CI:12.99-15.68, Z=20.90, P < 0.001), WMD=20.94(95%CI:9.28-22.59, Z=5.88, P < 0.001)]. Barthel index and Modified Rankin Scale score were similar between the two groups [WMD=6.98(95%CI:-2.89-16.85, Z=1.39, P=0.166), WMD=-0.04(95%CI:-0.16 to 0.24, Z=0.44, P=0.663)]. Except for Modified Rankin Scale score, the scores of National Institutes of Health Stroke Scale, Barthel index, Fugl-Myer movement assessment and functional independence measure score were significantly improved at all other time points.
CONCLUSION: Mesenchymal stem cell transplantation can improve the neurological deficit, motor function and daily living ability of patients with ischemic stroke.

Key words: mesenchymal stem cell, ischemic stroke, stroke, motor function, daily life, transplantation, neurological function, meta-analysis

CLC Number:

Hu Fei, Wang Jie. Safety and efficacy of mesenchymal stem cells in the treatment of ischemic stroke: a meta-analysis[J]. Chinese Journal of Tissue Engineering Research, 2023, 27(1): 76-82.

Figures/Tables 11

References

[1] WANG W, JIANG B, SUN H, et al. Prevalence, Incidence, and Mortality of Stroke in China: Results from a Nationwide Population-Based Survey of 480 687 Adults. Circulation. 2017;135(8):759-771.
[2] STURM JW, DEWEY HM, DONNAN GA, et al. Handicap after stroke: how does it relate to disability, perception of recovery, and stroke subtype?: the north North East Melbourne Stroke Incidence Study (NEMESIS). Stroke. 2002;33(3):762-768.
[3] LIU JC, HUANG HY, HSU YT. Hyperthyroidism and thrombophilia in cerebral arterial and venous thrombosis: a case report and critical review. Neurologist. 2015;19(2):53-55.
[4] CHAVALI S, SHUKLA U, CHAUTA S. Traumatic subclavian arterial thrombosis presenting with cerebral infarct--a case report. Heart Lung Circ. 2014;23(10):e202-e206.
[5] OU C, HUANG W, YUEN MM. A computational model based on fibrin accumulation for the prediction of stasis thrombosis following flow-diverting treatment in cerebral aneurysms. Med Biol Eng Comput. 2017;55(1):89-99.
[6] LI T, XIA M, GAO Y, et al. Human umbilical cord mesenchymal stem cells: an overview of their potential in cell-based therapy. Expert Opin Biol Ther. 2015;15(9):1293-1306.
[7] MISHRA PJ, BANERJEE D. Activation and Differentiation of Mesenchymal Stem Cells. Methods Mol Biol. 2017;1554:201-209.
[8] CHANG F, XIONG W, WANG D, et al. Facilitation of ultrasonic microvesicles on homing and molecular mechanism of bone marrow mesenchymal stem cells in cerebral infarction patients. Eur Rev Med Pharmacol Sci. 2017;21(17):3916-3923.
[9] DING DC, CHANG YH, SHYU WC, et al. Human umbilical cord mesenchymal stem cells: a new era for stem cell therapy. Cell Transplant. 2015;24(3):339-347.
[10] ANKRUM JA, ONG JF, KARP JM. Mesenchymal stem cells: immune evasive, not immune privileged. Nat Biotechnol. 2014;32(3):252-260.
[11] UCCELLI A, MORETTA L, PISTOIA V. Mesenchymal stem cells in health and disease. Nat Rev Immunol. 2008;8(9):726-736.
[12] PORADA CD, Almeida-Porada G. Mesenchymal stem cells as therapeutics and vehicles for gene and drug delivery. Adv Drug Deliv Rev. 2010;62(12):1156-1166.
[13] SCUTERI A, MILOSO M, FOUDAH D, et al. Mesenchymal stem cells neuronal differentiation ability: a real perspective for nervous system repair? Curr Stem Cell Res Ther. 2011;6(2):82-92.
[14] WANG X, KIMBREL EA, IJICHI K, et al. Human ESC-derived MSCs outperform bone marrow MSCs in the treatment of an EAE model of multiple sclerosis. Stem Cell Reports. 2014; 3(1):115-130.
[15] HATANO S. Experience from a multicentre stroke register: a preliminary report. Bull World Health Organ. 1976;54(5):541-553.
[16] 陈文斗,李江涛,张效北,等.骨髓间充质干细胞移植治疗脑梗死临床分析[J].吉林医学,2012,33(21):4522.
[17] 宋承伟,汪萍,胡晓琴,等.脐带血间充质干细胞移植治疗脑梗死的临床疗效观察[J].临床合理用药杂志,2013,6(5): 69-70.
[18] 冯龚,田国萍,李莉,等.人脐带血间充质干细胞治疗脑梗死的临床疗效研究[J].实用心脑肺血管病杂志,2014,22(1): 28-30.
[19] 何振东.骨髓间充质干细胞移植改善脑梗死患者神经功能机制研究[J].亚太传统医药,2012,8(12):126-127.
[20] 胡晴,曹梦莹,李瑞芳,等. 脐带间充质干细胞治疗脑梗死的安全性与有效性[J].武汉大学学报(医学版),2013,34(1): 55-60,70.
[21] 刘定华,韩伯军,洪珊珊,等.自体骨髓间充质神经干细胞移植治疗脑梗死的疗效观察[J].中华物理医学与康复杂志, 2014,36(6):425-428.
[22] 孟宪国,朱士文,高华,等.自体骨髓间充质干细胞移植治疗脑梗死:6个月随访[J].中国组织工程研究与临床康复, 2009,13(32):6374-6378.
[23] 田立平,王晶晶,赵凯龙.人脐带血间充质干细胞治疗脑梗死的临床效果观察[J].临床合理用药杂志,2018,11(26): 109-110.
[24] 王晓虹,王苏平,徐广鑫,等.脐带血有核细胞治疗脑梗死后遗症近期疗效观察[J].转化医学杂志,2013,2(6):332-335.
[25] 王旭,张志彬,贾芙蓉,等. 自体骨髓间充质干细胞介入移植治疗脑梗死临床研究[J].吉林医学,2014,35(2):237-239.
[26] 谢旭芳,刘诗英,金光华,等.自体骨髓间充质干细胞移植治疗脑梗死的临床分析[J].检验医学与临床,2014,11(21): 2955-2957.
[27] 赵新利,王艳,张彩霞,等.骨髓间充质干细胞治疗在脑卒中的研究[J].环球中医药,2013(S2):157.
[28] FANG J, GUO Y, TAN S, et al. Autologous Endothelial Progenitor Cells Transplantation for Acute Ischemic Stroke: A 4-Year Follow-Up Study. Stem Cells Transl Med. 2019;8(1):14-21.
[29] JAILLARD A, HOMMEL M, MOISAN A, et al. Autologous Mesenchymal Stem Cells Improve Motor Recovery in Subacute Ischemic Stroke: a Randomized Clinical Trial. Transl Stroke Res. 2020;11(5):910-923.
[30] LEE JS, HONG JM, MOON GJ, et al. A long-term follow-up study of intravenous autologous mesenchymal stem cell transplantation in patients with ischemic stroke. Stem Cells. 2010;28(6):1099-1106.
[31] SAVITZ SI, YAVAGAL D, RAPPARD G, et al. A Phase 2 Randomized, Sham-Controlled Trial of Internal Carotid Artery Infusion of Autologous Bone Marrow-Derived ALD-401 Cells in Patients With Recent Stable Ischemic Stroke (RECOVER-Stroke). Circulation. 2019;139(2):192-205.
[32] LAW ZK, TAN HJ, CHIN SP, et al. The effects of intravenous infusion of autologous mesenchymal stromal cells in patients with subacute middle cerebral artery infarct: a phase 2 randomized controlled trial on safety, tolerability and efficacy. Cytotherapy. 2021;23(9):833-840.
[33] LEE J, CHANG WH, CHUNG JW, et al. Efficacy of Intravenous Mesenchymal Stem Cells for Motor Recovery After Ischemic Stroke: A Neuroimaging Study. Stroke. 2022;53(1):20-28.
[34] DE CELIS-RUIZ E, FUENTES B, MONICHE F, et al. Allogeneic adipose tissue-derived mesenchymal stem cells in ischaemic stroke (AMASCIS-02): a phase IIb, multicentre, double-blind, placebo-controlled clinical trial protocol. BMJ Open. 2021;11(8):e051790.
[35] 沈大鹏.脐带间充质干细胞早期单次移植治疗对急性脑梗死的神经功能恢复[J]. 中国伤残医学,2015,23(2):26-28.
[36] CAPLAN AI. Mesenchymal stem cells. J Orthop Res. 1991;9(5):641-650.
[37] JIAO Y, LIU YW, CHEN WG, et al. Neuroregeneration and functional recovery after stroke: advancing neural stem cell therapy toward clinical application. Neural Regen Res. 2021;16(1):80-92.
[38] BANG OY, LEE JS, LEE PH, et al. Autologous mesenchymal stem cell transplantation in stroke patients. Ann Neurol. 2005; 57(6):874-882.
[39] JIANG Y, ZHU W, ZHU J, et al. Feasibility of delivering mesenchymal stem cells via catheter to the proximal end of the lesion artery in patients with stroke in the territory of the middle cerebral artery. Cell Transplant. 2013;22(12):2291-2298.
[40] BEKER M, CAGLAYAN AB, BEKER MC, et al. Lentivirally administered glial cell line-derived neurotrophic factor promotes post-ischemic neurological recovery, brain remodeling and contralesional pyramidal tract plasticity by regulating axonal growth inhibitors and guidance proteins. Exp Neurol. 2020;331:113364.
[41] SHIOTA Y, NAGAI A, SHEIKH AM, et al. Transplantation of a bone marrow mesenchymal stem cell line increases neuronal progenitor cell migration in a cerebral ischemia animal model. Sci Rep. 2018;8(1):14951.
[42] FORBES LH, ANDREWS MR. Advances in human stem cell therapies: pre-clinical studies and the outlook for central nervous system regeneration. Neural Regen Res. 2021;16(4):614-617.
[43] LIU J, CHUAH YJ, FU J, et al. Co-culture of human umbilical vein endothelial cells and human bone marrow stromal cells into a micro-cavitary gelatin-methacrylate hydrogel system to enhance angiogenesis. Mater Sci Eng C Mater Biol Appl. 2019; 102:906-916.